Does RADIUM RA-223 DICHLORIDE Cause Disease progression? 208 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 208 reports of Disease progression have been filed in association with RADIUM RA-223 DICHLORIDE (Xofigo). This represents 4.3% of all adverse event reports for RADIUM RA-223 DICHLORIDE.
208
Reports of Disease progression with RADIUM RA-223 DICHLORIDE
4.3%
of all RADIUM RA-223 DICHLORIDE reports
19
Deaths
14
Hospitalizations
How Dangerous Is Disease progression From RADIUM RA-223 DICHLORIDE?
Of the 208 reports, 19 (9.1%) resulted in death, 14 (6.7%) required hospitalization.
Is Disease progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RADIUM RA-223 DICHLORIDE. However, 208 reports have been filed with the FAERS database.
What Other Side Effects Does RADIUM RA-223 DICHLORIDE Cause?
Prostatic specific antigen increased (449)
Hormone-refractory prostate cancer (441)
Death (376)
Anaemia (324)
Metastases to bone (315)
General physical health deterioration (308)
Fatigue (242)
Haemoglobin decreased (236)
Prostate cancer (234)
Nausea (221)
What Other Drugs Cause Disease progression?
RITUXIMAB (7,282)
CYCLOPHOSPHAMIDE (7,100)
DOXORUBICIN (6,165)
VINCRISTINE (5,252)
PREDNISONE (5,096)
BEVACIZUMAB (4,653)
DEXAMETHASONE (4,545)
CARBOPLATIN (4,538)
CAPECITABINE (3,808)
ETOPOSIDE (3,776)
Which RADIUM RA-223 DICHLORIDE Alternatives Have Lower Disease progression Risk?
RADIUM RA-223 DICHLORIDE vs RALOXIFENE
RADIUM RA-223 DICHLORIDE vs RALTEGRAVIR
RADIUM RA-223 DICHLORIDE vs RALTITREXED
RADIUM RA-223 DICHLORIDE vs RAMELTEON
RADIUM RA-223 DICHLORIDE vs RAMIPRIL